Mechanism of Linderae Radix against gastric cancer based on network pharmacology and in vitro experimental validation.
10.19540/j.cnki.cjcmm.20220529.501
- Author:
Xiao LIANG
1
;
Jun-Hao ZHANG
1
;
Hao-Tian BAI
1
;
Ya-Lan LI
1
;
Shu-Hui SUN
1
;
Qian-Qian ZHANG
1
;
Jing YANG
2
;
Rui WANG
1
Author Information
1. Heilongjiang University of Traditional Chinese Medicine Harbin 150040, China.
2. Basic Medical College of Heilongjiang University of Traditional Chinese Medicine Harbin 150040, China.
- Publication Type:Journal Article
- Keywords:
Linderae Radix;
experimental validation;
gastric cancer;
molecular mechanism;
network pharmacology
- MeSH:
Antigens, Neoplasm;
Drugs, Chinese Herbal/therapeutic use*;
Humans;
Lindera/chemistry*;
Medicine, Chinese Traditional;
Molecular Docking Simulation;
Network Pharmacology;
Stomach Neoplasms/drug therapy*;
Tumor Suppressor Protein p53;
bcl-2-Associated X Protein
- From:
China Journal of Chinese Materia Medica
2022;47(18):5008-5021
- CountryChina
- Language:Chinese
-
Abstract:
The present study explored the main active ingredients and the underlying mechanism of Linderae Radix the treatment of gastric cancer by network pharmacology, molecular docking, and in vitro cell experiments. TCMSP, OMIM and GeneCards database were used to obtain the active ingredients of Linderae Radix to predict the related targets of both Linderae Radix and gastric cancer. After screening the common potential action targets, the STRING database was used to construct the PPI network for protein interaction of the two common targets. Enrichment analysis of GO and KEGG by DAVID database. Based on STRING and DAVID platform data, Cytoscape software was used to construct an "active ingredient-target" network and an "active ingredient-target-pathway" network. Molecular docking was performed using the AutoDock Vina to predict the binding of the active components to the key action targets, and finally the key targets and pathways were verified in vitro. According to the prediction results, there were 9 active components, 179 related targets of Radix Linderae, 107 common targets of Linderae Radix and gastric cancer, 693 biological processes, 57 cell compositions, and 129 molecular functions involved in the targets, and 161 signaling pathways involved in tumor antigen p53, hypoxia-indu-cible factor 1, etc. Molecular docking results showed that the core component, jimadone, had high binding activity with TP53. Finally, in an in vitro experiment, the screened radix linderae active ingredient gemmadone is used for preliminarily verifying the core targets and pathways of the human gastric cancer cell SGC-7901, The results showed that germacrone could significantly inhibit the proliferation of gastric cancer cells and induce the apoptosis of SGC-7901 by regulating the expression of p53, Bax, Bcl-2 and other key proteins. In summary, Radix Linderae can control the occurrence and development of gastric cancer through multi-components, multi-targets and multi-pathways, which will provide theoretical basis for further clinical discussion on the mechanism of Radix Linderae in treating gastric cancer.
